Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Total Current Liabilities: 2013-2025

Historic Total Current Liabilities for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to $372.3 million.

  • Coherus Oncology's Total Current Liabilities rose 25.96% to $372.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $372.3 million, marking a year-over-year increase of 25.96%. This contributed to the annual value of $283.0 million for FY2024, which is 14.71% down from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Total Current Liabilities is $372.3 million, which was up 41.22% from $263.6 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Total Current Liabilities peaked at $538.3 million during Q1 2024, and registered a low of $123.4 million during Q1 2023.
  • Moreover, its 3-year median value for Total Current Liabilities was $283.0 million (2024), whereas its average is $303.2 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first spiked by 336.20% in 2024, then plummeted by 52.62% in 2025.
  • Quarterly analysis of 5 years shows Coherus Oncology's Total Current Liabilities stood at $165.3 million in 2021, then fell by 16.11% to $138.7 million in 2022, then skyrocketed by 139.21% to $331.8 million in 2023, then declined by 14.71% to $283.0 million in 2024, then rose by 25.96% to $372.3 million in 2025.
  • Its last three reported values are $372.3 million in Q3 2025, $263.6 million for Q2 2025, and $255.0 million during Q1 2025.